Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial.
New oral drug for rheumatoid arthritis doubled remission rates and held joint damage at bay through a full year.
Deucravacitinib (TYK2 inhibitor) achieved ACR20 of 54.2% vs 34.1% placebo at 16 weeks (P<0.001) with sustained structural damage inhibition through 52 weeks and a favorable safety profile. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- phase_3_rct
- Category
- Other
- Maturity
- Potentially Practice-Changing
- Journal
- Ann Rheum Dis
Why it surfaced
Phase 3 confirmation of a selective TYK2 inhibitor in PsA with 52-week durability data; important because deucravacitinib is the first-in-class oral TYK2-selective agent with favorable selectivity over JAK1/2/3, addressing a safety concern that has limited JAK inhibitor adoption.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.